Abstract:People with T1D (PWT1D) use many strategies to avoid nocturnal hypoglycemia (NH), however, the current evidence on these strategies is limited. Technologies such as continuous subcutaneous insulin infusion (CSII) or continuous glucose monitors (CGM) could help reduce NH and possibly alter PWT1D’ management behaviors. Aim: To describe PWT1D’ preferred NH prevention strategies according to their use of technology. Methods: Self-reported data from an online registry of PWT1D were analyzed. To describe which NH prevention strategies are most often used, we ran a χ2 test with a post hoc pairwise comparison of the groups based on their mode of insulin delivery and glucose monitoring (CSII + self-monitoring of blood glucose (SMBG); CSII + CGM; multiple daily injections (MDI) + CGM; MDI + SMBG). Results: Among 767 adults (64% female, mean age 45 ± 15 years, T1D duration 25 ± 14 years) 42% used MDI + CGM, 40% CSII + CGM, 5% CSII + SMBG, and 13% MDI + SMBG. About 67% reported waking up ≥1 time in the past month due to NH symptoms. The most widely used strategies were verifying bedtime glycemia (71%), having an evening/bedtime snack (60%), and/or reducing nocturnal basal insulin (30%). PWT1D using CSII + CGM or CSII + SMBG relied more on basal insulin reduction (36% and 33.3%, respectively) compared to those using MDI + CGM (26%) or MDI + SMBG (19%). Less PWT1D using CSII + CGM reported having a snack to prevent NH (51%), compared to CSII + SBMG (61%), MDI + CGM (66%), and MDI + SBGM (67%) groups (p<0.001). Conclusion: Results suggest that PWT1D using technology choose different strategies to avoid NH than non-users. CSII users relying on basal insulin adjustment was expected as CSII offers more flexibility for insulin delivery. Snacks remain a popular strategy to prevent NH but are less used by PWT1D on CSII + CGM. While our findings provide some real-life insight into the methods PWT1D use to avoid NH, the efficacy of these strategies still needs further investigation. Disclosure M. K. Talbo: None. V. Messier: Other Relationship; Self; Eli Lilly and Company. K. Desjardins: None. R. Rabasa-lhoret: Advisory Panel; Self; Bayer Inc., Covance Inc., Insulet Corporation, Pfizer Inc., Other Relationship; Self; Abbott, AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Dexcom, Inc., Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Medtronic, Merck & Co., Inc., Novo Nordisk, Sanofi-Aventis, Research Support; Self; Canadian Institutes of Health Research, Cystic Fibrosis Canada, Diabetes Canada, JDRF, National Institutes of Health, Prometic, Société Francophone du Diabète, Speaker’s Bureau; Self; CMS Canadian Medical&Surgical Knowledge Translation Research Group, CPD Network. A. Brazeau: None. T. Peters: None. Funding Canadian Institutes of Health Research (JT1-157204); JDRF (4-SRA-2018-651-Q-R)

Delayed prandial insulin boluses are an important determinant of blood glucose control and relate to fear of hypoglycemia in people with type 1 diabetes on advanced technologies

Using an Online Disturbance Rejection and Anticipation System to Reduce Hyperglycemia in a Fully Closed-Loop Artificial Pancreas System

Effect of diabetes technologies on the fear of hypoglycaemia among people living with type 1 diabetes: a systematic review and meta-analysis

Fear of Hypoglycemia and Diabetes Distress: Expected Reduction by Glucose Prediction

Prevalence of hypoglycemic conditions in adolescents with type 1 diabetes mellitus in real clinical practice

Flash Glucose Monitoring System Help Reduce the Frequency of Hypoglycemia and Hypoglycemic Fear Behavior in Type 1 Diabetes Patients

Postprandial Glucose Control With Different Hybrid Closed-Loop Systems According to Type of Meal in Adults With Type 1 Diabetes

Glycemic Variability and Its Responses to Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes.

Fear of hypoglycemia in patients with type 1 and 2 diabetes: a systematic review

Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-Sectional Survey

Impact Of Flash Glucose Monitoring On The Fear Of Hypoglycemia Phenomenon In Adults With Type 1 Diabetes

Gender differences in reported frequency and consequences of hypoglycemia among adults living with type 1 diabetes: Results from the BETTER registry

Objectively Measured Adherence in Adolescents With Type 1 Diabetes on Multiple Daily Injections and Insulin Pump Therapy

74-LB: Impact of Mild and Moderate High Blood Glucose Excursions on Daily Living in Adults with Type 1 Diabetes

Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies

Postprandial glucose‐management strategies in type 1 diabetes: Current approaches and prospects with precision medicine and artificial intelligence

Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy: Results from a pooled analysis of insulin lispro clinical trials

Intermittent closed-loop blood glucose control for people with type 1 diabetes on multiple daily injections

Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices

393-P: Technology Use and Hypoglycemia in Type 1 Diabetes: Insights from the BETTER Registry

136-OR: Nocturnal Hypoglycemia Prevention Strategies Used by People with Type 1 Diabetes According to Their Insulin Delivery and Blood Glucose Monitoring Technology